One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Cue Biopharma, Inc.
CUE · NCM · Healthcare · Biotechnology
Current price
$19.17
52-week range
$4.98 - $45.50
Market cap
$139.24M
Balance sheet
Healthy
-74.29x Concerning
Net cash $14.34M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 37.1% last year.
- Risk Return on equity was -1603.5% last year — the company lost money on shareholders' equity.
What this company does
Cue Biopharma, Inc.
Cue Biopharma is developing new medicines to treat immune system problems, with its main focus on a drug for allergies that is currently in testing. Since it's still in the development stage, its money mostly comes from research funding rather than selling products, which means its future success depends on how well its experimental treatments work in trials.
How the company got here
Cue Biopharma was founded in 2014 and is headquartered in Boston, Massachusetts. It was formerly known as Imagen Biopharma, Inc., changing its name in October 2016. The company is a clinical-stage biopharmaceutical firm focused on developing therapies for immunological disorders. Its foundation is built upon research into the Immuno-STAT platform, which aims to precisely target T cells without broadly suppressing the immune system. This platform technology has been central to the company's progression from a research-focused entity to a clinical-stage company with multiple programs in development.
What it actually does
Cue Biopharma develops therapies designed to precisely target and modulate specific T cells within the body. These therapies are intended to treat diseases where the immune system is either overactive or misdirected, such as autoimmune diseases and cancer. The company's core technology, the Immuno-STAT platform, acts like a highly specific key, unlocking or calming down particular immune cells without affecting the rest of the body's defenses. This targeted approach aims to offer greater effectiveness and fewer side effects compared to treatments that broadly suppress the immune system.
CUE-221 (Allergic Diseases)
Cue Biopharma's lead program in allergic diseases is CUE-221, an investigational antibody designed to treat IgE-mediated allergic conditions. IgE (Immunoglobulin E) is a type of antibody involved in allergic reactions. CUE-221 works in two ways: it neutralizes existing IgE, which helps prevent allergic reactions, and it also reduces the body's production of new IgE. This dual action is intended to provide more comprehensive and lasting control over allergic diseases like chronic spontaneous urticaria (CSU), a type of hives, and potentially food allergies. The company has reported positive results from Phase 2 trials for CUE-221 in CSU, showing significant symptom improvement and a favorable safety profile.
CUE-401 (Autoimmune Diseases)
CUE-401 is Cue Biopharma's lead candidate for treating autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. This therapy is a bifunctional molecule that combines two important immune-regulating signals: Interleukin-2 (IL-2) and Transforming Growth Factor beta (TGF-β). The goal of CUE-401 is to restore immune balance by promoting the development and activity of regulatory T cells (Tregs). Tregs are a type of immune cell that helps prevent the immune system from attacking the body's own cells. By expanding and modulating Tregs, CUE-401 aims to induce immune tolerance and reduce inflammation, potentially offering a new way to manage autoimmune conditions. The company has received positive feedback from regulatory bodies regarding its plan to initiate clinical trials for CUE-401.
Immuno-STAT Platform (Oncology and Autoimmune Diseases)
The Immuno-STAT platform is the foundational technology that underpins Cue Biopharma's therapeutic development across both oncology (cancer) and autoimmune diseases. It's designed to create biologics (therapeutic proteins) that can precisely target and modulate specific T cells, which are key players in the immune system. Unlike treatments that broadly suppress immunity, Immuno-STAT aims to selectively activate or deactivate T cells that are involved in a particular disease, such as cancer cells or cells causing autoimmune reactions. This targeted approach is intended to maximize therapeutic effect while minimizing off-target side effects. The company has ongoing research and development applying this platform to various cancer types and autoimmune conditions, with some programs like CUE-101 in earlier stages of clinical development for HPV-positive cancers.
What management is betting on now
Cue Biopharma's management is focused on advancing its lead drug candidates, CUE-221 for allergic diseases and CUE-401 for autoimmune diseases, through clinical trials and towards potential regulatory approval. They are also continuing to leverage and expand the capabilities of their proprietary Immuno-STAT platform for developing new therapies in both oncology and autoimmune indications. A key strategy involves forming collaborations and partnerships with larger pharmaceutical companies to co-develop and commercialize these therapies, sharing the development risks and costs while accessing expertise and resources. The company is prioritizing the generation of robust clinical data to demonstrate the safety and efficacy of its drug candidates, which is crucial for attracting further investment and potential partnerships.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-7.53M
FY2024 Q4
$-9.03M
FY2025 Q1
$-8.32M
FY2025 Q2
$-3.44M
FY2025 Q3
$-9.02M
FY2025 Q4
$-1.08M
FY2026 Q1
$-11.06M
FY2026 Q2
$-29.00M
Revenue
$7.88M
Net income
$-153.07M
Diluted EPS
-24.14
Operating cash flow
$-29.00M
Free cash flow
$-29.00M
Fetching…
Sources
Revenue
$5.69M
Net income
$-5.18M
Diluted EPS
-1.08
Operating cash flow
$-10.94M
Free cash flow
$-11.06M
Fetching…
Sources
Revenue
$21.94M
Net income
$1.58M
Diluted EPS
0.05
Operating cash flow
$-1.08M
Free cash flow
$-1.08M
Fetching…
Sources
Revenue
$2.15M
Net income
$-7.45M
Diluted EPS
-0.07
Operating cash flow
$-9.02M
Free cash flow
$-9.02M
Fetching…
Sources
Revenue
$2.95M
Net income
$-8.48M
Diluted EPS
-0.09
Operating cash flow
$-3.42M
Free cash flow
$-3.44M
Fetching…
Sources
Revenue
$421.00K
Net income
$-12.26M
Diluted EPS
-0.17
Operating cash flow
$-8.17M
Free cash flow
$-8.32M
Fetching…
Sources
Revenue
$1.58M
Net income
$-9.50M
Diluted EPS
-0.10
Operating cash flow
$-9.03M
Free cash flow
$-9.03M
Fetching…
Sources
Revenue
$3.34M
Net income
$-8.66M
Diluted EPS
-0.17
Operating cash flow
$-7.53M
Free cash flow
$-7.53M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $19.17
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $14.3M - more cash than debt. Interest coverage -74.3x.
Net debt
$-14.34M
Interest coverage
-74.29x
Cue Biopharma, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
CUE
BASELINE
Cue Biopharma, Inc.
Total debt $3.08M Interest coverage -74.29x This is the baseline the peer rows are being compared against.
Total debt $21.86M Interest coverage -8,473.33x Neither company has much profit cushion over interest right now.
Total debt $29.00M Interest coverage -2.73x Neither company has much profit cushion over interest right now.
Total debt $4.39M Interest coverage -4.30x Neither company has much profit cushion over interest right now.
Total debt $252.22M Interest coverage -3.58x Neither company has much profit cushion over interest right now.
Total debt $162.20M Interest coverage 12.90x This peer still has a real interest-payment cushion, while CUE does not.
What you should know
The case for and against CUE
1 Reward
1 Risk
Rewards
-
Revenue grew 37.1% last year.
Risks
-
Return on equity was -1603.5% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-39.93x
P/B
43.37x
P/S
3.70x
EV/EBITDA
-1.25x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-99.2%
Operating margin
-262.0%
Net margin
0.0%
ROE
-1,603.5%
ROA
-172.7%
Health
Liquidity and balance-sheet strength
Debt / equity
1.33x
Current ratio
1.25x
Quick ratio
1.07x
Total debt
$3.08M
Total cash
$17.41M
Growth
How the business has been compounding
Revenue TTM
$37.65M
Revenue 5Y CAGR
16.4%
EPS TTM
-29.59
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-50.05M
Free CF TTM
$-21.86M
FCF margin
-58.1%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—